Get the Stockscreener App
132.20
0.56%
-0.74
After Hours:
132.20
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $132.20, with a volume of 5.06M.
It is down -0.56% in the last 24 hours and down -1.55% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.94
Open:
$132.26
24h Volume:
5.06M
Relative Volume:
0.82
Market Cap:
$230.09B
Revenue:
$43.11B
Net Income/Loss:
$13.94B
P/E Ratio:
16.57
EPS:
7.98
Net Cash Flow:
$6.78B
1W Performance:
-0.35%
1M Performance:
-1.55%
6M Performance:
-3.60%
1Y Performance:
+16.11%
1-Day Range:
$131.61
$133.09
1-Week Range:
$130.21
$134.32
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.20 | 231.38B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
108.14 | 158.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
393.11 | 149.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.99 | 119.16B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
80.21 | 47.52B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Top Research Reports for Broadcom, T-Mobile & Abbott - Yahoo Finance
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Buy Abbott Laboratories (ABT) If You’re Worried About COVID, Says Jim Cramer - MSN
Jared Moskowitz trades in Abbott Laboratories, AbbVie, and Goldman Sachs stocks - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
How to escape a deep drawdown in Abbott LaboratoriesTrade Exit Summary & Verified Short-Term Plans - Newser
Real time social sentiment graph for Abbott LaboratoriesWeekly Risk Summary & High Yield Equity Trading Tips - Newser
FDA recalls Abbott’s Heartmate power supply - BioWorld MedTech
Oncology Molecular Diagnostics Market Size Drives USD 9.76 Billion by 2034 - GlobeNewswire Inc.
Piper Sandler reiterates Overweight rating on Abbott Labs stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight rating on Abbott Labs stock - Investing.com
What institutional flow reveals about Abbott LaboratoriesTrade Risk Report & Smart Money Movement Alerts - Newser
What is the target price for Abbott Laboratories stockWeekly Trade Summary & Free Community Supported Trade Ideas - خودرو بانک
Ranking Abbott Laboratories among high performing stocks via toolsGap Down & Low Risk Growth Stock Ideas - Newser
How to use a screener to detect Abbott Laboratories breakoutsPortfolio Gains Summary & Safe Entry Zone Identification - Newser
Can Abbott Laboratories deliver consistent dividends2025 Buyback Activity & Safe Capital Investment Plans - خودرو بانک
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Strong Fundamentals and Bearish Technicals - AInvest
Returns Are Gaining Momentum At Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories falls after setting Q3 outlook below consensus - MSN
Clinical Nutrition Market Poised for Transformative Growth - openPR.com
Abbott India Limited's (NSE:ABBOTINDIA) top owners are public companies with 75% stake, while 17% is held by individual investors - simplywall.st
Abbott Laboratories Climbs to 148th in Trading Volume as Institutional Investors Diverge on Bets Analysts Split on Ratings and Defensive Stock Performance Stands Out - AInvest
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments [Video] - AOL.com
Abbott to take $200 million tariff hit: What it means for patients - TheStreet
Using data models to predict Abbott Laboratories stock movementBull Run & Weekly High Potential Stock Alerts - Newser
Abbott Laboratories stock trend outlook and recovery pathWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
Medtronic advances Abbott partnership with FDA nod - MedTech Dive
Tools to assess Abbott Laboratories’s risk profileJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Medtronic wins FDA nod to integrate Abbott’s Instinct sensor with MiniMed 780G - Seeking Alpha
Medtronic gets FDA OK to integrate Minimed with Abbott’s Instinct - BioWorld MedTech
How to track smart money flows in Abbott LaboratoriesJuly 2025 Update & Expert Curated Trade Ideas - Newser
How to integrate Abbott Laboratories into portfolio analysis toolsPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - Newser
Can technical indicators confirm Abbott Laboratories’s reversalJuly 2025 PreEarnings & Weekly High Momentum Picks - Newser
Is Abbott Laboratories stock poised for growthBond Market & Long-Term Safe Investment Plans - Newser
How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks? - MSN
Is now a turning point for Abbott Laboratories2025 Risk Factors & Expert Curated Trade Setups - Newser
Jim Cramer Shares Little Known Potential Catalyst For Abbott Laboratories (ABT) - MSN
Is Abbott Laboratories stock undervalued right nowQuarterly Profit Review & Expert Curated Trade Setup Alerts - خودرو بانک
Analyzing net buyer seller activity in Abbott LaboratoriesEarnings Recap Summary & Fast Entry Momentum Trade Alerts - Newser
Measuring Abbott Laboratories’s beta against major indicesWeekly Investment Report & Weekly Hot Stock Watchlists - Newser
What earnings revisions data tells us about Abbott LaboratoriesJuly 2025 Update & Consistent Profit Alerts - Newser
Price action breakdown for Abbott LaboratoriesShort Setup & AI Powered Market Trend Analysis - Newser
Real time pattern detection on Abbott Laboratories stockQuarterly Portfolio Review & Low Volatility Stock Suggestions - Newser
Abbott Laboratories Shows Early Signs of Technical Strength getLinesFromResByArray error: size == 0 - thegnnews.com
Does Abbott Laboratories show high probability of reboundMarket Trend Summary & Entry Point Confirmation Alerts - Newser
Does Abbott Laboratories fit your quant trading modelWeekly Trend Summary & Low Risk High Win Rate Stock Picks - Newser
What MACD and RSI say about Abbott LaboratoriesWeekly Gains Summary & Long-Term Capital Growth Ideas - Newser
Abbott Laboratories Eyes Synlait Milk Acquisition: Implications for Investment Narrative and Sector Focus - AInvest
A Look at Abbott Laboratories’s Valuation Following Strong Medical Device Launches and Regulatory Milestones - simplywall.st
Abbott’s Possible Pokeno Acquisition Might Change the Case for Investing in Abbott Laboratories (ABT) - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):